Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER for Fatigue in MDD
NCT01254305Phase 2Completed
- Sponsor
- Forest Laboratories
- Start
- Apr 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levomilnacipran in major depressive disorder (MDD) (3 arms), sponsored by Forest Laboratories. Primary endpoints: Clinical Global Impression of Severity for Fatigue at 8 weeks and Patient Global Impressions of Severity for Fatigue at 8 weeks. Started Apr 2011; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01254305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254305.